These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33369070)

  • 1. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
    Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
    Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes.
    Shameli A; Dharmani-Khan P; Auer I; Shabani-Rad MT
    Leuk Res; 2023 Nov; 134():107401. PubMed ID: 37774446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
    Rajab A; Porwit A
    Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
    Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
    Li Y; Beck RC; Moore EM
    Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
    Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
    Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.
    Tang G; Jorgensen LJ; Zhou Y; Hu Y; Kersh M; Garcia-Manero G; Medeiros LJ; Wang SA
    Leuk Res; 2012 Aug; 36(8):974-81. PubMed ID: 22626984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.
    Toft-Petersen M; Nederby L; Kjeldsen E; Kerndrup GB; Brown GD; Hokland P; Stidsholt Roug A
    Br J Haematol; 2016 Nov; 175(3):393-401. PubMed ID: 27612176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C; Tzankov A
    Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
    Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.
    Moon HW; Huh JW; Lee M; Hong KS; Chung WS
    Korean J Lab Med; 2010 Apr; 30(2):97-104. PubMed ID: 20445324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloblasts transition to megakaryoblastic immunophenotypes over time in some patients with myelodysplastic syndromes.
    Ogata K; Mochimaru Y; Sei K; Kawahara N; Ogata M; Yamamoto Y
    PLoS One; 2023; 18(9):e0291662. PubMed ID: 37729123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
    Mangaonkar AA; Swoboda DM; Lasho TL; Finke C; Ketterling RP; Reichard KK; Komrokji R; Padron E; Patnaik MM
    Leuk Res; 2023 Aug; 131():107340. PubMed ID: 37356165
    [No Abstract]   [Full Text] [Related]  

  • 16. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study.
    Chauhan R; Singh J; Sharma C; Dange P; Chopra A; Mahapatra M; Pati H
    Leuk Res; 2021 Aug; 107():106651. PubMed ID: 34218155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
    Behbehani GK; Finck R; Samusik N; Sridhar K; Fantl WJ; Greenberg PL; Nolan GP
    Cytometry B Clin Cytom; 2020 Mar; 98(2):131-145. PubMed ID: 31917512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes.
    Kuykendall AT; Tokumori FC; Komrokji RS
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.